Breast Cancer (HER2-Enriched) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Breast Cancer (HER2-Enriched)
HER2-enriched breast cancer, also known as HER2-positive breast cancer, accounts for about 15-20% of all breast cancer diagnoses. It's defined by cancer cells having too many copies of the HER2 (human epidermal growth factor receptor 2) gene, which produces HER2 proteins. These proteins are receptors on the surface of breast cells that play a crucial role in cell growth, division, and repair. When there's an overabundance of HER2 receptors, breast cells can grow and divide uncontrollably, leading to a more aggressive form of cancer. Understanding your HER2 status is vital for determining the most effective treatment path.
Historically, HER2-positive breast cancer was considered to have a poorer prognosis. However, the development of targeted therapies has revolutionized treatment and significantly improved outcomes. Common treatments for HER2-enriched breast cancer often include a combination of approaches. Targeted therapies are central, specifically designed to block the HER2 protein's activity. Medications like trastuzumab (Herceptin), pertuzumab (Perjeta), ado-trastuzumab emtansine
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.